HOFBF (Hofseth BioCare ASA) LT-Debt-to-Total-Asset: 0.59 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOFBF Hofseth BioCare ASA HOFBF
51 GF Score
Price $0.17
GF Value $0.26
! 6 Warning Signs
View Full Analysis

What is Hofseth BioCare ASA LT-Debt-to-Total-Asset?

Hofseth BioCare ASA HOFBF 51 LT-Debt-to-Total-Asset is 0.59 as of Mar. 2026. GuruFocus rates HOFBF with a GF Score™ of 51/100 and a GF Value™ of $0.26. The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hofseth BioCare ASA's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.59.

Hofseth BioCare ASA's long-term debt to total assets ratio increased from Mar. 2025 (0.43) to Mar. 2026 (0.59). It may suggest that Hofseth BioCare ASA is progressively becoming more dependent on debt to grow their business.

Hofseth BioCare ASA  (OTCPK:HOFBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hofseth BioCare ASA LT-Debt-to-Total-Asset Related Terms

Hofseth BioCare ASA LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Hofseth BioCare ASA's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hofseth BioCare ASA LT-Debt-to-Total-Asset Chart

Hofseth BioCare ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.22 0.25 0.33 0.58

Hofseth BioCare ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.53 0.52 0.58 0.59
HOFBF
51GF Score
Hofseth BioCare ASA HOFBF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hofseth BioCare ASA LT-Debt-to-Total-Asset Calculation

Hofseth BioCare ASA's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=22.617/39.01
=0.58

Hofseth BioCare ASA's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=22.717/38.238
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.59 mean?
Hofseth BioCare ASA (HOFBF) has a LT-Debt-to-Total-Asset of 0.59 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hofseth BioCare ASA and its competitors.
Is Hofseth BioCare ASA's LT-Debt-to-Total-Asset too high?
Hofseth BioCare ASA's current LT-Debt-to-Total-Asset is 0.59. Overall, Hofseth BioCare ASA has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Hofseth BioCare ASA's LT-Debt-to-Total-Asset compare to KHC and GIS?
Hofseth BioCare ASA's LT-Debt-to-Total-Asset of 0.59 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Consumer Packaged Goods company?
A good LT-Debt-to-Total-Asset depends on the Consumer Packaged Goods industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hofseth BioCare ASA and its competitors. Hofseth BioCare ASA's current LT-Debt-to-Total-Asset is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hofseth BioCare ASA stock overvalued right now?
Hofseth BioCare ASA (HOFBF) has a current LT-Debt-to-Total-Asset of 0.59. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.59. Hofseth BioCare ASA's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Hofseth BioCare ASA (HOFBF), the current LT-Debt-to-Total-Asset is 0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hofseth BioCare ASA (HOFBF) Overvalued in 2026?

Based on GuruFocus' analysis, Hofseth BioCare ASA stock appears to be undervalued. The current stock price of $0.17 is trading 35.9% below its estimated GF Value™ of $0.26.

Key valuation signals for HOFBF:

  • LT-Debt-to-Total-Asset: 0.59
  • GF Value™: $0.26 vs. price of $0.17 (35.9% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the HOFBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hofseth BioCare ASA Business Description

Address Keiser Wilhelmsgate 24, Aalesund, NOR, 6003
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its brands, which also generate revenue, include salmon oil (OmeGo), water-soluble protein (ProGo), calcium/collagen (CalGo and NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
51GF Score

Get the complete analysis for HOFBF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price
$0.26
GF Value